studies Joanna Moncrieff (1997) quotes our study, but appears not to have read it. She writes â€oe¿ The largest and longest of them [lithium augmentation studies], which followed up 34 patients for three weeks, was negative (Stein & Barnadt, 1988 )â€•,whereas we actually reported on 24 patients followed up for nine weeks and that there were significant lithium augmentation effects at weeks three, six and nine.
The reason we then reported on 24 patients, which was three-quarters of the way through the trial, was the occurrence of the Second British Lithium Congress, which we regarded as an important occasion. Our final and definitive report (Stein & Bernadt, 1993) which Dr Mon cnieff did not quote was of 34 patients who over a nine-week trial showed significant benefit from lithium augmenta tion for treatment-resistant depression.
We found that when added to existing tnicyclic medication, which was taken in maximally tolerated doses, lithium 750 mg per day had a greaten antidepres sant effect than low-dose lithium (250 mg per day), which was no better than placebo. Dr Moncnieff also states that our earlier study reported low compliance rates, but neither of our publications mentioned compliance and our impression was of good compliance. The review is also inaccurate in stating that ours is the largest lithium augmentation study in that Katona et a! (1995) had 61 patients. Another study that should have been quoted is Dinan & Barry (1989) who showed that lithium augmentation was as effective as electroconvulsive therapy in tnicyclic non-responders.
Dr Moncnieff is right to draw attention to methodological weaknesses in lithium studies. Because lithium treatment is cheap, research about it has never attracted fund ing of the scale lavished on the newer antidepressants and there remain important uncertainties about its clinical use. 
Grey matter correlates of syndromes In schizophrenia
Sir: In a sample of people with schizo phrenia Chua et a! (1997) reported the interesting finding that there was a signifi cant and positive correlation between the disonganisation scone and relative volumes of grey matter in medial temporal lobe structures. They mention that this finding â€oe¿ may seem at odds with the reportedly reduced size of this region in schizophrenia. However, our observations were made within a group of schizophrenics, and reflected differences among schizophrenics rather than differences between schizophre nics and controlsâ€•. They proceeded to discuss reasons why increased volume of grey matter in medial temporal lobe struc tunes might result from some pathological process in schizophrenia, for example, lack of neuronal pruning.
There is another possible interpreta tion which may be somewhat more parsimonious.
It is possible that the finding reflects normal volume of medial temporal lobe grey matter in patients with the disorganisation syndrome, and abnor mal reductions of temporal lobe grey matter in other people with schizophrenia. This interpretation is consistent with many studies which have found that the volume of medial temporal lobe grey matter is abnormally reduced in schizo phnenia (Suddath et a!, 1990; Breier et a!, 1992; Rossi et a!, 1994; Fukuzako et a!, 1996) . It is also consistent with a previous report of an association between reduced mesiotemporal tissue volume and higher ratings of the Brief Psychiatric Rating Scale psychosis factor (Bogerts et a!, 1993) .
Hypotheses based on these alternative interpretations could be tested in future studies by including a normal comparison group.
David E. Rous MarylandPsychiatric Research
Center,University of Maryland at Baltimore,P0 Box 21247, Baltimore, MD 21228, USA
Comorbidity of mental disorders with substance misuse
Sir: A recent editorial in the Journa! on comorbidity of mental disorders with sub stance misuse proposed that staff in addic tion services should be trained to identify anxiety and affective disorders in their clientele (Hall & Farrell, 1997) . A third of persons with an alcohol use disorder (37%) have another mental disorder and half of those with other drug use disorders have comorbid mental disorder (Regien et a!, 1990) . Purchasers are increasingly using services provided by non-statutory agen cies, which are often cheaper than those provided by psychiatric addiction services, in part because there is less emphasis on nursing and psychiatric training within the staff skills mix.
